Mesoblast shares surge after Ryoncil therapy passes US Medicare milestone
Make us a preferred source
Make us a preferred source on Google
The news: Shares in Mesoblast soared in morning trade after the biotech announced that a US Medicare and Medicaid Services code for its Ryoncil cell therapy became active on 1 October 2025, making it “easier to bill and pay for”.
The numbers: At 10:41am AEST, Mesoblast shares rallied 15% to $2.92.
The context: Mesoblast’s Ryoncil cell therapy – designed to treat children with steroid-refractory acute graft-versus-host disease (SR-aGvHD), a high mortality risk complication of stem cell transplants – received a permanent healthcare common procedure coding system J-code.
According to Mesoblast, the code provides a clear and specific “billing pathway for Ryoncil by Medicaid, facilitating reimbursement and broader patient access”. The code is also used by commercial healthcare and insurance providers.
What they said: “A permanent J-code is a critical element for successful commercialisation of rare disease products, ensuring more efficient billing and enabling timely access to Ryoncil for children with life-threatening SR-aGvHD,” Mesoblast chief executive Silviu Itescu said.
The source: ASX
